Release Date: April 23, 2021
Expiration Date: April 23, 2022
Activity Overview
This video-based program is designed to help healthcare professionals explore the management and treatment of atopic dermatitis (AD) through a unique perspective, putting the patient voice front and center. A patient and caregiver will lend their expertise to this program by sharing their journey with AD. This online activity focuses on the complex pathophysiology and disease burden of AD, clinical presentation and basic management of the disease, efficacy and safety of current therapies recommended for symptom control, and emerging new agents that may substantially improve patient quality of life.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AbbVie Inc.
Target Audience
This online educational activity is directed toward dermatologists, primary care physicians, nurse practitioners, physician assistants, and additional members of the multidisciplinary care team.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the symptoms of atopic dermatitis that impact patient quality of life
- Evaluate current efficacy and safety data for established therapies used in the management of atopic dermatitis
- Analyze evidence regarding emerging targeted therapies for the management of atopic dermatitis in adult patients
- Develop treatment plans for adult patients with atopic dermatitis based on patient preferences and goals of therapy
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
Chair
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, MI
Disclosures: Grant/Research: Pfizer, AbbVie, Incyte, Dermavant, Arcutis Biotherapeutics, Ortho Dermatologics; Consultant: Pfizer, Abbvie, lncyte, Dermavant, Arcutis Biotherapeutics, Ortho Dermatologics, Sanofi, Regeneron, Amgen; Speaker’s Bureau: Pfizer, Amgen.
Faculty
Clinical Assistant Professor of Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Grant/Research: AbbVie, Regeneron/Sanofi Genzyme, AOBiome; Consultant: Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO Pharma, AbbVie, Lilly, Micreos, L'Oréal, Johnson & Johnson, Unilever, VYNE Therapeutics, Theraplex, IntraDerm Pharmaceuticals, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Arbonne, Amyris, Bodewell, Burt's Bees; Speaker’s Bureau: Regeneron/Sanofi Genzyme, Pfizer, Lilly, LEO Pharma, Galderma, L'Oréal; Stock/Shareholder: Micreos, Altus Labs; Other: Royalties from Theraplex (Theraplex AIM).
Caregiver
Britney Berry
Britney Berry has no relevant financial relationships with ineligible companies.
Patient
Heaven Wiley
Heaven Wiley has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
